2019 Future of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments
The global demand for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline companies from advancing their products into Phase 3 or Phase 4.
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Report Description-
The 2019 pipeline study on Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline compounds.
The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline guide presents information on all active drugs currently being developed for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.
Details of current status, R&D progress and latest developments for every Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline candidate are analyzed.
Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) drug candidates.
Drug development companies, collaborators, originating companies, license providers and universities participating in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.
The report assists in identifying potential upcoming companies and drugs in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.
Scope of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline report includes-
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Report Description-
The 2019 pipeline study on Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline compounds.
The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline guide presents information on all active drugs currently being developed for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.
Details of current status, R&D progress and latest developments for every Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline candidate are analyzed.
Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) drug candidates.
Drug development companies, collaborators, originating companies, license providers and universities participating in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.
The report assists in identifying potential upcoming companies and drugs in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.
Scope of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline report includes-
- An overview of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) disease including symptoms, causes, diagnosis and available treatment options is provided.
- Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc
- Phase wise count of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline
- Company wise list of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline
- Mechanism of Action wise Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline
- For each pipeline candidate, the following details are provided
- Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)
- Current status of development
- Drug overview
- Mechanism of Action
- Pre-clinical and Clinical Trials/Results
- Company Overview and Recent Developments
- The report is designed to help industry executives promote the success and continued growth of their organizations
- Get clear understanding of the entire Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline, with details on active projects
- Stay ahead of the competition through comprehensive knowledge of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline progress
- Get in detail information of each product with updated information on each project along with key milestones
- Gain clear insights into companies participating in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
- Get trial information for each pipeline product under development
- Understand the pipeline structure in terms of mechanism of Action, phase and company
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) PIPELINE OVERVIEW
2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Research Methodology
3. EXECUTIVE SUMMARY
3.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development
3.2.1 Pre-clinical
3.2.2 Discovery
3.2.3 Phase
3.2.4Phase
3.3 Pipeline Drugs in Advanced Stage of Development
3.3.1 Phase
3.3.2 Pre-registration
3.4 Companies involved in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline, H1- 2019
3.5 Mechanism of Action wise Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Pipeline Candidates
4 GENEURO SA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) PIPELINE DETAILS
4.1 GeNeuro SA Business Profile
4.2 GeNeuro SA Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drug Details
4.3 Drug Snapshot
4.3.1 Originator
4.3.2 Collaborator/Co-Developer
4.3.3 Route of Administration
4.3.4 Orphan Drug/Fast Track/Special Designation
4.3.5 Geography
4.3.6 Type of Molecular Entity
4.3.7 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments
5 IMMUPHARMA PLC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) PIPELINE DETAILS
5.1 Immupharma Plc Business Profile
5.2 Immupharma Plc Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drug Details
5.3 Drug Snapshot
5.3.1 Originator
5.3.2 Collaborator/Co-Developer
5.3.3 Route of Administration
5.3.4 Orphan Drug/Fast Track/Special Designation
5.3.5 Geography
5.3.6 Type of Molecular Entity
5.3.7 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments
6 MOMENTA PHARMACEUTICALS INC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) PIPELINE DETAILS
6.1 Momenta Pharmaceuticals Inc Business Profile
6.2 Momenta Pharmaceuticals Inc Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drug Details
6.3 Drug Snapshot
6.3.1 Originator
6.3.2 Collaborator/Co-Developer
6.3.3 Route of Administration
6.3.4 Orphan Drug/Fast Track/Special Designation
6.3.5 Geography
6.3.6 Type of Molecular Entity
6.3.7 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments
7 OCTAPHARMA AG CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) PIPELINE DETAILS
7.1 Octapharma AG Business Profile
7.2 Octapharma AG Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drug Details
7.3 Drug Snapshot
7.3.1 Originator
7.3.2 Collaborator/Co-Developer
7.3.3 Route of Administration
7.3.4 Orphan Drug/Fast Track/Special Designation
7.3.5 Geography
7.3.6 Type of Molecular Entity
7.3.7 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments
8 PFIZER INC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) PIPELINE DETAILS
8.1 Pfizer Inc Business Profile
8.2 Pfizer Inc Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drug Details
8.3 Drug Snapshot
8.3.1 Originator
8.3.2 Collaborator/Co-Developer
8.3.3 Route of Administration
8.3.4 Orphan Drug/Fast Track/Special Designation
8.3.5 Geography
8.3.6 Type of Molecular Entity
8.3.7 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments
9 SHIRE PLC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) PIPELINE DETAILS
9.1 Shire Plc Business Profile
9.2 Shire Plc Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drug Details
9.3 Drug Snapshot
9.3.1 Originator
9.3.2 Collaborator/Co-Developer
9.3.3 Route of Administration
9.3.4 Orphan Drug/Fast Track/Special Designation
9.3.5 Geography
9.3.6 Type of Molecular Entity
9.3.7 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments
10 TEIJIN PHARMA LTD CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) PIPELINE DETAILS
10.1 Teijin Pharma Ltd Business Profile
10.2 Teijin Pharma Ltd Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drug Details
10.3 Drug Snapshot
10.3.1 Originator
10.3.2 Collaborator/Co-Developer
10.3.3 Route of Administration
10.3.4 Orphan Drug/Fast Track/Special Designation
10.3.5 Geography
10.3.6 Type of Molecular Entity
10.3.7 Current Status
10.4 Drug Overview
10.5 Drug Mechanism of Action
10.6 Clinical/Pre-clinical Trial Details
10.7 Latest Drug Developments
11 UCB PHARMA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) PIPELINE DETAILS
11.1 UCB Pharma Business Profile
11.2 UCB Pharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drug Details
11.3 Drug Snapshot
11.3.1 Originator
11.3.2 Collaborator/Co-Developer
11.3.3 Route of Administration
11.3.4 Orphan Drug/Fast Track/Special Designation
11.3.5 Geography
11.3.6 Type of Molecular Entity
11.3.7 Current Status
11.4 Drug Overview
11.5 Drug Mechanism of Action
11.6 Clinical/Pre-clinical Trial Details
11.7 Latest Drug Developments
12. LATEST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) DRUG PIPELINE DEVELOPMENTS, 2019
13. APPENDIX
13.1 About Us
13.2 Sources and Methodology
13.3 Contact Information
1.1 List of Tables
1.2 List of Figures
2. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) PIPELINE OVERVIEW
2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Research Methodology
3. EXECUTIVE SUMMARY
3.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development
3.2.1 Pre-clinical
3.2.2 Discovery
3.2.3 Phase
3.2.4Phase
3.3 Pipeline Drugs in Advanced Stage of Development
3.3.1 Phase
3.3.2 Pre-registration
3.4 Companies involved in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline, H1- 2019
3.5 Mechanism of Action wise Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Pipeline Candidates
4 GENEURO SA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) PIPELINE DETAILS
4.1 GeNeuro SA Business Profile
4.2 GeNeuro SA Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drug Details
4.3 Drug Snapshot
4.3.1 Originator
4.3.2 Collaborator/Co-Developer
4.3.3 Route of Administration
4.3.4 Orphan Drug/Fast Track/Special Designation
4.3.5 Geography
4.3.6 Type of Molecular Entity
4.3.7 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments
5 IMMUPHARMA PLC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) PIPELINE DETAILS
5.1 Immupharma Plc Business Profile
5.2 Immupharma Plc Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drug Details
5.3 Drug Snapshot
5.3.1 Originator
5.3.2 Collaborator/Co-Developer
5.3.3 Route of Administration
5.3.4 Orphan Drug/Fast Track/Special Designation
5.3.5 Geography
5.3.6 Type of Molecular Entity
5.3.7 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments
6 MOMENTA PHARMACEUTICALS INC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) PIPELINE DETAILS
6.1 Momenta Pharmaceuticals Inc Business Profile
6.2 Momenta Pharmaceuticals Inc Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drug Details
6.3 Drug Snapshot
6.3.1 Originator
6.3.2 Collaborator/Co-Developer
6.3.3 Route of Administration
6.3.4 Orphan Drug/Fast Track/Special Designation
6.3.5 Geography
6.3.6 Type of Molecular Entity
6.3.7 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments
7 OCTAPHARMA AG CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) PIPELINE DETAILS
7.1 Octapharma AG Business Profile
7.2 Octapharma AG Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drug Details
7.3 Drug Snapshot
7.3.1 Originator
7.3.2 Collaborator/Co-Developer
7.3.3 Route of Administration
7.3.4 Orphan Drug/Fast Track/Special Designation
7.3.5 Geography
7.3.6 Type of Molecular Entity
7.3.7 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments
8 PFIZER INC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) PIPELINE DETAILS
8.1 Pfizer Inc Business Profile
8.2 Pfizer Inc Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drug Details
8.3 Drug Snapshot
8.3.1 Originator
8.3.2 Collaborator/Co-Developer
8.3.3 Route of Administration
8.3.4 Orphan Drug/Fast Track/Special Designation
8.3.5 Geography
8.3.6 Type of Molecular Entity
8.3.7 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments
9 SHIRE PLC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) PIPELINE DETAILS
9.1 Shire Plc Business Profile
9.2 Shire Plc Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drug Details
9.3 Drug Snapshot
9.3.1 Originator
9.3.2 Collaborator/Co-Developer
9.3.3 Route of Administration
9.3.4 Orphan Drug/Fast Track/Special Designation
9.3.5 Geography
9.3.6 Type of Molecular Entity
9.3.7 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments
10 TEIJIN PHARMA LTD CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) PIPELINE DETAILS
10.1 Teijin Pharma Ltd Business Profile
10.2 Teijin Pharma Ltd Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drug Details
10.3 Drug Snapshot
10.3.1 Originator
10.3.2 Collaborator/Co-Developer
10.3.3 Route of Administration
10.3.4 Orphan Drug/Fast Track/Special Designation
10.3.5 Geography
10.3.6 Type of Molecular Entity
10.3.7 Current Status
10.4 Drug Overview
10.5 Drug Mechanism of Action
10.6 Clinical/Pre-clinical Trial Details
10.7 Latest Drug Developments
11 UCB PHARMA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) PIPELINE DETAILS
11.1 UCB Pharma Business Profile
11.2 UCB Pharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drug Details
11.3 Drug Snapshot
11.3.1 Originator
11.3.2 Collaborator/Co-Developer
11.3.3 Route of Administration
11.3.4 Orphan Drug/Fast Track/Special Designation
11.3.5 Geography
11.3.6 Type of Molecular Entity
11.3.7 Current Status
11.4 Drug Overview
11.5 Drug Mechanism of Action
11.6 Clinical/Pre-clinical Trial Details
11.7 Latest Drug Developments
12. LATEST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) DRUG PIPELINE DEVELOPMENTS, 2019
13. APPENDIX
13.1 About Us
13.2 Sources and Methodology
13.3 Contact Information
